Embecta (EMBC) Stock Price, News & Analysis

Company Overview

Embecta Corporation (NASDAQ: EMBC) is a global diabetes-care company that develops and manufactures products designed to support insulin delivery and diabetes management. Its portfolio includes pen needles, insulin syringes, safety needles, lancets and other injection-related products used by people with diabetes and healthcare professionals.

The company also provides solutions intended to improve the safety, convenience and effectiveness of diabetes care, including connected and digital tools associated with insulin delivery. Embecta serves customers through healthcare providers, pharmacies, distributors and other channels in markets around the world.

Embecta became an independent publicly traded company in April 2022 after being separated from Becton, Dickinson and Company, where its operations formed the former Diabetes Care business. The company is headquartered in Franklin Lakes, New Jersey, and is led by Chief Executive Officer Devdatt “Dev” Kurdikar.

Key Stats

• Today's Range: $5.65 to $5.96
• 50-Day Range: $3.25 to $5.93
• 52-Week Range: $2.77 to $14.91
• Volume: 990,891 shs
• Average Volume: 1.10 million shs
• Market Capitalization: $326.36 million
• P/E Ratio: 3.89
• Dividend Yield: 0.69%
• Price Target: $11.00
• Consensus Rating: Reduce

Embecta Stock Analysis - MarketRank™

Embecta scored higher than 78% of companies evaluated by MarketBeat, and ranked 119th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Embecta has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Embecta has a consensus price target of $11.00, representing about 91.0% upside from its current price of $5.76.

Amount of Analyst Coverage

Embecta has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -4.35%

Earnings Growth

Earnings for Embecta are expected to decrease by -4.35% in the coming year, from $1.84 to $1.76 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Embecta is 3.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of Embecta is 3.89, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.79.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.92% of the float of Embecta has been sold short.

Short Interest Ratio / Days to Cover

Embecta has a short interest ratio ("days to cover") of 4.46.

Change versus previous month

Short interest in Embecta has recently decreased by 11.45%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Embecta has a dividend yield of 0.67%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Embecta does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Embecta is 2.70%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Embecta will have a dividend payout ratio of 2.27% next year. This indicates that Embecta will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.60

News Sentiment

Embecta has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Embecta this week, compared to 8 articles on an average week.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Embecta in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $297,197.00 in company stock, which represents 0.0911% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Embecta insiders have bought 803.17% more of their company's stock than they have sold. Specifically, they have bought $334,200.00 in company stock and sold $37,003.00 in company stock.

Percentage Held by Insiders

1.30% of the stock of Embecta is held by insiders.

Percentage Held by Institutions

93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Record date for 9/15 Dividend: 8/27/2026
• Ex-Dividend for 9/15 Dividend: 8/27/2026
• Dividend Payable: 9/15/2026
• Today: 9/30/2026
• Fiscal Year End: 9/30/2026
• Next Earnings (Estimated): 11/24/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:EMBC
• CIK: 1872789
• Web: www.embecta.com
• Phone: 201-847-6880
• Fax: N/A
• Employees: 1,850
• Year Founded: 2022

Price Target and Rating

• Average Price Target for Embecta: $11.00
• High Price Target: $25.00
• Low Price Target: $3.00
• Potential Upside/Downside: +91.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.48
• Trailing P/E Ratio: 3.89
• Forward P/E Ratio: 3.13
• P/E Growth: N/A
• Net Income: $95.40 million
• Net Margins: 8.59%
• Pretax Margin: 12.27%
• Return on Equity: -19.25%
• Return on Assets: 10.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.68
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $1.08 billion
• Price / Sales: 0.30
• Cash Flow: $3.89 per share
• Price / Cash Flow: 1.48
• Book Value: ($11.12) per share
• Price / Book: -0.52

Miscellaneous

• Outstanding Shares: 56,660,000
• Free Float: 55,923,000
• Market Cap: $326.36 million
• Optionable: Optionable
• Beta: 0.86